Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been
collaborating across the healthcare innovation ecosystem ranging from
large pharmaceutical companies to the smallest of biotech companies,
from government agencies to academic institutions to address the
COVID-19 global health care crisis. Researchers and scientists have been
relentlessly working to develop an investigational antiviral compound
to treat SARS-CoV-2, which causes the current pandemic of coronavirus
infections (COVID-19), a vaccine to prevent infection as well as
evaluating other therapies that have scientific potential to help
infected patients fight the virus.
“We are committed to making the impossible possible,” said Dr. Albert
Bourla, Chairman and CEO. “In the spirit of the Five Point Plan that
Pfizer issued, we are facing this public health challenge head on by
collaborating with industry partners and academic institutions to
develop potential novel approaches to prevent and treat COVID-19. Our
researchers and scientists also have been exploring potential new uses
of existing medicines in Pfizer’s portfolio to help infected patients
globally. We are leaving no stone unturned as we explore every option to
help provide society with a treatment or cure.”
Pfizer announced key advances in its commitment to protect humankind
from this escalating pandemic and prepare the industry to better respond
to future global health crises.
Anti-Viral Compound Screening
Pfizer confirmed a lead compound and analogues are potent inhibitors
of the SARS-CoV-2 3C-like (3CL) protease, based on the results of
initial screening assays. In addition, preliminary data suggest the lead
protease inhibitor shows antiviral activity against SARS-CoV-2.
Consequently, Pfizer will perform pre-clinical confirmatory studies,
including further anti-viral profiling and assessment of the suitability
of the lead molecule for IV administration clinically. In parallel, the
company is also investing in materials that will accelerate the start
of a potential clinical study of the lead molecule to third quarter
2020, three or more months in advance of earlier estimates, subject to
positive completion of the pre-clinical confirmatory studies.
Applying Pfizer’s Long History in Vaccine Research Development Expertise to Finalize Our Agreement with BioNTech
Pfizer Inc. and BioNTech SE have entered into a global collaboration
agreement to co-develop BioNTech’s potential first-in-class, mRNA-based
coronavirus vaccine program aimed at preventing COVID-19 infection. In
March 2020, the companies announced a letter of intent to collaborate
and began working together at that time. The two companies plan to
jointly conduct clinical trials for the COVID-19 vaccine candidates
initially in the United States and Europe across multiple research
sites. BioNTech and Pfizer intend to initiate clinical trials as early
as the end of April 2020, assuming regulatory clearance. The companies
estimate that there is potential to supply millions of vaccine doses by
the end of 2020 subject to technical success of the development program
and approval of regulatory authorities and then rapidly scale up to
capacity to produce hundreds of millions of doses in 2021. For the terms
of the agreement, please see the press release page of
Pfizer’s website.
Analysis of Azithromycin as an Agent with Antiviral Activity
In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers will publish a review in
Clinical Pharmacology and Therapeutics
which assesses published in vitro and clinical data regarding
azithromycin as an agent with antiviral properties. This open access
review may serve to facilitate the use of azithromycin in future
research on COVID-19. Azithromycin is not approved for the treatment of
viral infections.
Studying Pfizer’s Existing Medicines for Critical Patient Populations in Need
Pfizer Inc. and the Liverpool School of Tropical Medicine’s
Respiratory Infection Clinical Research Group are launching two new
studies to provide insights on the interaction between S. pneumoniae and
SARS-CoV-2. Pfizer is expected to finalize in the coming days, a
research collaboration agreement with Liverpool to provide funding and
in-kind laboratory testing support for this research. The studies (SAFER
study (SARS-CoV-2 Acquisition in Frontline Health Care Workers –
Evaluation to Inform Response) and the FASTER study (Facilitating A SARS
CoV-2 Test for Rapid triage)) will help demonstrate whether patients
infected with COVID-19 have a higher risk of also developing
pneumococcal pneumonia and if having both infections leads to more
severe disease and poorer outcomes. The SAFER study will enroll 100
healthcare workers at the Royal Liverpool Hospital and examine rates of
SARS-CoV-2 acquisition and dynamics of pneumococcal colonization. The
FASTER study will recruit 400 patients from the infectious disease ward
at the Royal Liverpool Hospital suspected of having coronavirus.
Enrollment has already begun, and data are expected over the next few
months.
An independent Phase 2 investigator-initiated study for the use of
tofacitinib, an oral Janus Kinase (JAK) inhibitor, in patients with
SARS-CoV-2 interstitial pneumonia is planned to be initiated in Italy
later this week. The study is supported by a Pfizer grant. For more
details about the study, please see
clinicaltrials.gov.
Pfizer is also in discussions with other institutions about
additional studies involving tofacitinib and potentially other immune
modulators in our portfolio. This research is based on the hypothesis
that JAK inhibition could mitigate systemic and alveolar inflammation in
patients with COVID-19-related pneumonia by inhibiting essential
cytokine signaling involved in immune-mediated inflammatory response
that could lead to damage of the lungs, resulting in acute respiratory
distress syndrome in patients with COVID-19-related pneumonia. It is
important to note, tofacitinib is not currently approved for this use
and should not be used in patients with an active serious infection.
“While this work can generally take years, we are working to find
opportunities to save time wherever we can and work in parallel rather
than in a linear capacity,” said Mikael Dolsten, Chief Scientific
Officer and President, Worldwide Research, Development & Medical,
Pfizer. “This pursuit requires a crucial multi-pronged approach with a
deep collaboration and partnership across the health innovation
ecosystem – from the academic community, industry partners, policymakers
and regulatory bodies. We announced in March that we are collaborating
with BioNTech to co-develop a potential first-in-class, mRNA-based
COVID-19 vaccine. A public threat like coronavirus COVID-19 pushes each
of us to urgently bring forward our resources and expertise to overcome
this most challenging moment in the medical history of this century.”
The company will continue to share information from its portfolio and
emerging candidates that could benefit the many companies and
organizations who are working quickly to provide solutions to combat
this unprecedented healthcare crisis.